Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
See what results to expect from zero based budgeting and how to monitor progress with clear, actionable metrics.
19,375 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Investors are jittery as AI powerhouses push for faster adoption, while critics warn of overhype. This piece breaks d...
Divisadero Street Capital Management upped its stake in Dave (DAVE), fueling questions about a potential buying oppor...
SpaceX stocks have traded below their IPO price, stirring questions about value and risk. This guide delivers a pract...
Facing a pullback, Bitcoin still offers two compelling catalysts for action before June 2026. Learn the data-backed r...
A landmark ruling would change who pays tariff costs and could lift earnings for U.S. companies. Markets react as inv...
A new defense-focused ETF began trading in July 2026, joining VistaShares’ space and robotics funds as investors chas...
Kick off your weekend with focused, actionable investing reads. This guide helps you pick credible sources, turn insi...
A historic music chart moment becomes a practical lesson in money management. This article translates that milestone ...
A hedge fund made a sizable new bet on Centuri Holdings, disclosed in an SEC filing. This article breaks down the num...
A growing literacy gap among Gen Z students entering college is prompting schools to rethink instruction and budget f...
When oil surges grab the headlines, it’s easy to assume inflation will follow. In reality, inflation data often reass...